Celecoxib

證據等級: L5

預測適應症: 10 個

Celecoxib: From Arthritis to Inflammatory Spondylopathy

One-Sentence Summary

Celecoxib is a selective COX-2 inhibitor globally approved for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, though it currently holds no marketing authorization in Italy. The TxGNN model predicts it may be effective for Inflammatory Spondylopathy (encompassing ankylosing spondylitis and axial spondyloarthritis), with 19 clinical trials and 20 publications currently supporting this direction — including multiple completed Phase 3 randomized controlled trials establishing Level 1 evidence.

Quick Overview

Item	Content
Original Indication	Globally approved for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; no Italian authorization on record
Predicted New Indication	Inflammatory Spondylopathy
TxGNN Prediction Score	99.80%
Evidence Level	L1
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the primary data source. Based on published evidence, Celecoxib is the first selective cyclooxygenase-2 (COX-2) inhibitor introduced into clinical practice. It was specifically designed to provide anti-inflammatory and analgesic efficacy comparable to non-selective NSAIDs, while sparing COX-1 to reduce upper gastrointestinal toxicity. By selectively blocking COX-2, celecoxib suppresses the synthesis of pro-inflammatory prostaglandins — particularly PGE₂ — which are central mediators of pain, joint swelling, entheseal inflammation, and tissue destruction in inflammatory musculoskeletal diseases.

Inflammatory spondylopathy (ankylosing spondylitis / axial spondyloarthritis) is a chronic inflammatory disease in which the COX-2-mediated prostaglandin cascade plays a particularly prominent pathological role. Celecoxib's predicted benefit operates through at least three converging mechanisms: (1) reducing synovial and entheseal inflammation; (2) inhibiting osteoclast activation to slow erosive bone damage; and (3) — most notably, a 2025 meta-analysis demonstrated that celecoxib is the only NSAID shown to inhibit radiographic syndesmophyte (spinal bridging bone) formation, implying a direct bone-modifying effect beyond classical anti-inflammation, with the precise mechanism still under active investigation.

The biological and clinical logic connecting celecoxib to inflammatory spondylopathy is exceptionally strong. Published EU regulatory reviews confirm that celecoxib (Celebrex®) is already indicated in the European Union for symptomatic treatment of ankylosing spondylitis in adults. The TxGNN prediction therefore reflects an existing global evidence base that has not yet been formalised into an Italian marketing authorisation — making this a market access opportunity rather than a purely exploratory repurposing hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00648141	Phase 3	Completed	458	12-week double-blind RCT: Celecoxib 200mg QD vs 200mg BID vs Diclofenac 75mg SR BID in AS — compared safety and efficacy across dose regimens
NCT00762463	Phase 3	Completed	240	6-week double-blind RCT with 6-week extension in Chinese AS patients: Celecoxib 200mg QD vs Diclofenac 75mg SR — assessed symptom relief and safety
NCT02528201	Phase 4	Completed	330	12-week double-blind dose-confirmation trial: Celecoxib 200mg QD vs 400mg QD vs Diclofenac TID in AS — confirmed post-marketing efficacy and safety data
NCT01934933	Phase 4	Completed	150	54-week open-label RCT: Etanercept + Celecoxib vs Etanercept alone vs Celecoxib alone in active AS — primary endpoint MRI SPARCC score of sacroiliac joint
NCT02758782	Phase 4	Completed	156	CONSUL trial: Celecoxib + Golimumab vs Golimumab monotherapy in AS — evaluated impact on radiographic structural damage progression over 2 years
NCT03190603	Phase 4	Completed	12	MRI pilot study: NSAID effect on inflammatory lesion resolution in axial spondyloarthritis — assessed change from baseline in bone marrow oedema
NCT04115098	Phase 2	Terminated	42	N-of-1 trials comparing selective COX-2 vs non-selective COX inhibitors in axSpA — examined disease activity improvement and proteomic biomarkers
NCT01572675	N/A	Completed	547	French pharmacoepidemiology study on etoricoxib and celecoxib (Celebrex®) in routine clinical practice — real-world utilisation patterns
NCT03473665	Phase 4	Terminated	9	6-week double-blind RCT comparing 4 NSAIDs in axial spondyloarthritis — assessed pain score change at week 4 vs week 6
NCT02456363	Phase 2	Unknown	300	Registry project: Adalimumab + NSAIDs vs Adalimumab alone in ankylosing spondylitis — assessed safety and efficacy of combination strategy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39757202	2025	Systematic Review / Meta-analysis	BMB Reports	Celecoxib is the only NSAID demonstrated to inhibit radiographic bone progression in spondyloarthritis — proposed mechanism distinct from pure COX inhibition
40911151	2025	Umbrella Review	Drugs	Systematic synthesis of meta-analyses on celecoxib safety in chronic musculoskeletal conditions — comprehensive evaluation of cardiovascular, GI, and renal safety signals
38832489	2024	RCT	Scandinavian Journal of Rheumatology	Iguratimod + celecoxib vs celecoxib alone in active axSpA — randomised double-blind placebo-controlled trial assessing add-on efficacy and safety
38228361	2024	RCT	Annals of the Rheumatic Diseases	CONSUL trial results: adding celecoxib to golimumab did not significantly reduce radiographic spinal progression over 2 years vs TNFi monotherapy
36800138	2023	RCT / Clinical Study	Clinical Rheumatology	Imrecoxib and celecoxib both modulate sacroiliac joint inflammation in axSpA via changes in bone metabolism markers and angiogenesis indices
28626213	2017	RCT	Medical Science Monitor	Celecoxib 200mg BID vs imrecoxib 100mg BID in axSpA over 12 weeks — equivalent efficacy; both influenced serum DKK-1 levels correlated with imaging improvement
40028763	2025	Comparative Cohort	Scandinavian Journal of Rheumatology	Nationwide retrospective cohort in AS: cardiovascular disease and GI bleeding risk comparable between celecoxib and non-selective NSAIDs
16960941	2006	RCT	The Journal of Rheumatology	Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis — foundational Phase 3 efficacy data
27603385	2016	Population-based Cohort	Medicine	Taiwan NHI database (n=4,829 AS patients): celecoxib and sulfasalazine use negatively associated with coronary artery disease risk in AS
17983259	2007	Comprehensive Drug Review	Drugs	Celecoxib approved in multiple countries for OA, RA, JRA (≥2 years), and AS — decade of clinical practice review confirming broad musculoskeletal indication profile

Italy Market Information

Celecoxib currently holds no marketing authorization in Italy. There are no approved products, dosage forms, or licensed indications on record in the Italian regulatory database.

Note: Celecoxib (Celebrex®) is authorized in the European Union for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults, per published EU regulatory reviews. An Italian market entry would require submission to AIFA.

Safety Considerations

Please refer to the package insert for safety information.

Formal safety data (key warnings, contraindications, drug-drug interactions) were not retrievable from the Italian regulatory database for this drug. Clinical evidence in the literature does document cardiovascular and gastrointestinal risk profiles (see PMID 40911151 and 40028763), which should be reviewed as part of any regulatory submission or clinical protocol.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 3 RCTs and multiple Phase 4 trials directly evaluating celecoxib in ankylosing spondylitis / inflammatory spondylopathy establish L1 evidence. Celecoxib is already EU-approved for this indication in principle, and a 2025 meta-analysis suggests it may be the only NSAID with disease-modifying potential in spondyloarthritis — a clinically significant differentiator.

To proceed, the following is needed:

Regulatory pathway: Initiate AIFA marketing authorisation application for the ankylosing spondylitis / inflammatory spondylopathy indication, leveraging existing EMA evidence package
MOA documentation: Obtain complete mechanism of action data from DrugBank (DB00482) to support regulatory dossier and mechanistic rationale
Safety dossier: Retrieve AIFA SmPC / package insert for full Italian-compliant contraindications, warnings, and special population guidance
Drug interaction assessment: Formal DDI review for co-prescribing with TNF inhibitors (etanercept, golimumab, adalimumab), DMARDs, and corticosteroids — common in the target spondyloarthritis population
Cardiovascular risk plan: Define cardiovascular risk stratification and monitoring protocol for the target patient population, accounting for the known class-level COX-2 selective inhibitor cardiovascular signal
Paediatric consideration: Clarify whether the Italian submission will include the JIA/RF+ pJIA indication, given FDA approval for celecoxib in JIA patients ≥2 years (evidence: PMID 25057265)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.